Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | CA7 | P43166 | 3/20 | 0.34 |
| ▸ | CA9 | Q16790 | 3/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15929807 | 1.00 | LMNA (0.37) | LMNAKDM4ETSHRMEN1CYP3A4 | |
| SCHEMBL10478110 | 0.78 | LMNA (0.44) | LMNAKDM4ETSHRMEN1CYP3A4 | |
| SCHEMBL17145151 | 0.77 | MAOB (0.39) | LMNATSHRMEN1CYP3A4KMT2A | |
| SCHEMBL12867184 | 0.75 | LMNA (0.40) | LMNAKDM4ETSHRMEN1CYP3A4 | |
| SCHEMBL12867186 | 0.75 | LMNA (0.40) | LMNAKDM4ETSHRMEN1CYP3A4 | |
| SCHEMBL16646267 | 0.75 | LMNA (0.37) | LMNAKDM4ETSHRMEN1CYP3A4 | |
| SCHEMBL17145154 | 0.74 | LMNA (0.37) | LMNAKDM4ETSHRMEN1CYP3A4 | |
| SCHEMBL3455790 | 0.73 | LMNA (0.44) | LMNAKDM4ETSHRMEN1CYP3A4 | |
| SCHEMBL22434843 | 0.72 | TSHR (0.39) | LMNAKDM4ETSHRMEN1CYP3A4 | |
| SCHEMBL14283139 | 0.72 | KMT2A (0.41) | LMNAKDM4ETSHRCYP3A4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110040120-A1 | PREPARATION OF OSELTAMIVIR PHOSPHATE (TAMIFLU®) AND INTERMEDIATES STARTING FROM D-GLUCOSE OR D-XYLOSE | APOTEX PHARMACHEM INC. (CA) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110040120-A1 | PREPARATION OF OSELTAMIVIR PHOSPHATE (TAMIFLU®) AND INTERMEDIATES STARTING FROM D-GLUCOSE OR D-XYLOSE | G6PD, GALE, MGAM | LMNA 3190/4885KDM4E 1139/4885TSHR 3476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.